TOLLYS SAS logo

TOLLYS SAS

TOLLYS develops TolX100, an innovative immunotherapy targeting Toll-Like Receptor 3 (TLR3) in the field of cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]